Introduction
The postpartum period is increasingly understood as a continuum of maternal recovery, adaptation and vulnerability, not as a single visit at six weeks. The concept of the fourth trimester has helped reinforce this change by emphasizing that care after birth should address women’s physical, psychological and social needs in an ongoing and individualized way. The expression is used here as a clinical framework for the early postpartum transition and does not imply that pregnancy continues after birth.
1
Yet even within this broader model of postpartum care, the genitourinary and sexual health of breastfeeding women remains insufficiently recognized in routine clinical practice.
Many women experience changes in sexual wellbeing after childbirth, including dyspareunia, reduced lubrication, loss of sexual confidence, changes in desire and difficulties resuming intimacy. 2 , 3 These symptoms do not occur in isolation. They often coexist with fatigue, altered body image, perineal or pelvic floor morbidity, breastfeeding demands, urinary symptoms and the emotional transition into motherhood. Yet, for many women, such symptoms are either not volunteered or are normalized as an inevitable consequence of childbirth. For clinicians, this creates a familiar but clinically important blind spot: symptoms that are common may be mistaken for symptoms that do not require evaluation.
The recently proposed term genitourinary syndrome of lactation (GSL) offers a useful framework to describe a constellation of postpartum and lactation-related genital, urinary and sexual symptoms associated with the hormonal environment of breastfeeding.
4
The concept draws an intentional parallel with genitourinary syndrome of menopause (GSM), a term adopted to describe genital, sexual and urinary symptoms and signs related to reduced estrogen and other sex steroid activity involving the vulva, vestibule, vagina, urethra and bladder.
5
This analogy is clinically valuable, but it should not be applied simplistically. GSL is not menopause occurring in a younger woman. It arises in a distinct biological and emotional context: the postpartum period, lactation, recovery from birth, maternal fatigue, changing body image and the gradual reconstruction of sexual intimacy.
A recent systematic review on postpartum and lactation-related genitourinary symptoms highlighted the clinically relevant burden of vaginal dryness, vaginal atrophy, dyspareunia, urinary symptoms and sexual dysfunction among postpartum and lactating women.
6
These findings are consistent with the clinical observation that some breastfeeding women report symptoms that resemble hypoestrogenic vulvovaginal and urinary changes but are rarely explored systematically during postpartum visits.
Recognizing GSL should not be understood as an argument against breastfeeding, nor as an attempt to pathologize a physiological stage of maternal life. On the contrary, it provides an opportunity to support breastfeeding more completely by acknowledging the mother’s body, sexuality and quality of life. Breastfeeding can and should be promoted, protected and supported, but not idealized to the point that maternal genitourinary suffering becomes invisible. The purpose of this narrative perspective review is to synthesize the emerging evidence on GSL, distinguish it from other postpartum conditions, and propose a practical clinical framework for screening, differential diagnosis and breastfeeding-supportive management.
This article was prepared as a narrative perspective review and clinical framework, not as a systematic or scoping review. The evidence base was updated through 3 August 2026 using targeted searches of PubMed/MEDLINE from database inception. Search concepts combined terms for genitourinary syndrome of lactation, breastfeeding, lactation and postpartum status with terms for vulvovaginal symptoms, dyspareunia, sexual function, urinary symptoms, lactational amenorrhea, hypoestrogenism, pelvic floor dysfunction and relevant treatments. Additional focused searches addressed low-dose vaginal estrogen, vaginal prasterone, hyaluronic acid, pelvic floor rehabilitation, energy-based therapies and medication use during lactation. Reference lists of key reviews and consensus documents were also examined. The search concepts are reported in Supplementary Table S1 .
We prioritized the original GSL proposal, systematic reviews, peer-reviewed observational or interventional studies, consensus terminology documents and clinically relevant guidance. Because the objective was interpretive and forward-looking, no protocol was registered, no exhaustive duplicate study-selection or formal risk-of-bias process was undertaken, and no pooled effect estimate was calculated. PRISMA and a PICOS framework were therefore not applied. Throughout the article, direct postpartum or lactation-specific evidence is distinguished from evidence extrapolated from postmenopausal GSM and from areas where evidence remains preliminary.
New terminology should be introduced carefully. A name can clarify clinical reasoning, validate patient experience and create a common language for research, but it can also medicalize normal physiology if used without nuance. The value of GSL is not to assign a disease label to every breastfeeding woman; it is to make clinically meaningful and underreported symptoms easier to recognize and discuss.
GSM provides a useful precedent. It replaced narrower expressions such as vulvovaginal atrophy or atrophic vaginitis because they did not capture the full genital, sexual and urinary spectrum associated with reduced sex-steroid activity.
5
GSL may similarly help clinicians move beyond isolated descriptions of postpartum vaginal dryness or lactation-related dyspareunia toward an integrated assessment of vulvovaginal, urinary and sexual symptoms.
4
The analogy must remain bounded because lactation is physiological, dynamic and usually time-limited.
Terminology also matters because help-seeking is limited. In the MAMMI cohort, postpartum sexual health problems were common, while mixed-methods work showed that women often did not seek professional help despite persistent symptoms. 3 , 7 A named clinical concept can prompt clinicians to ask explicitly, validate symptoms and explain available options.
GSL should therefore function as a clinical lens rather than a shortcut diagnosis: a way to recognize a plausible breastfeeding-associated hormonal pattern while preserving assessment for perineal trauma, pelvic floor dysfunction, infection, dermatoses, urinary disease, pain syndromes and psychosocial distress.
The conceptual proximity between GSM and GSL is useful because it helps clinicians recognize a familiar biological pattern in a different stage of life. GSM was defined as a collection of symptoms and signs associated with a decrease in estrogen and other sex steroids, involving changes in the vulva, vestibule, vagina, urethra and bladder, and including genital, sexual and urinary manifestations.
5
GSL, as recently proposed, applies a related clinical logic to postpartum breastfeeding women, in whom lactation-associated hormonal changes may contribute to vulvovaginal dryness, atrophy, dyspareunia, urinary symptoms and sexual dysfunction. 4 , 6 The comparison between both syndromes is summarized in Table 1 . Table 1. Genitourinary syndrome of menopause and genitourinary syndrome of lactation: similarities and differences. Domain Genitourinary syndrome of menopause Genitourinary syndrome of lactation Clinical implication Life stage Perimenopause and postmenopause, usually in midlife and older women. Postpartum period, particularly during exclusive or prolonged breastfeeding. Position GSL as part of postpartum and fourth-trimester care. Endocrine background Chronic decline in estrogen and other sex steroids related to ovarian aging. Lactation-associated suppression of ovarian function, mediated by suckling-related prolactin and reduced hypothalamic-pituitary-ovarian pulsatility, with lower estradiol particularly during amenorrhea. The analogy with GSM is useful, but GSL has a different origin. Natural history Usually persistent and progressive without treatment. Potentially transient and linked to intensity and duration of breastfeeding, although symptoms may persist in some women. Avoid presenting GSL as a lifelong chronic condition. Main genital symptoms Vaginal dryness, burning, irritation, vulvar discomfort, reduced elasticity and mucosal fragility. Vaginal dryness, burning, irritation, fissuring, introital discomfort and postpartum vulvovaginal atrophy-like symptoms. Symptom overlap supports the conceptual bridge. Sexual symptoms Reduced lubrication, dyspareunia, discomfort, impaired sexual function and avoidance. Reduced lubrication, superficial dyspareunia, avoidance, reduced sexual confidence and secondary decrease in desire. GSL should be discussed as a sexual health issue, not only a mucosal problem. Urinary symptoms Urgency, dysuria, recurrent urinary tract infections, urinary discomfort and frequency. Urgency, frequency, urethral burning, dysuria-like discomfort, leakage or recurrent urinary complaints may coexist. Urinary symptoms should be included but are not diagnostically specific. Psychosocial context Aging, menopause transition, body image, sexual identity, chronicity and partner communication. Early motherhood, fatigue, sleep deprivation, breastfeeding demands, physical recovery, body changes and redefinition of intimacy. The postpartum context gives GSL distinct emotional and relational meaning. Barriers to recognition Symptoms often normalized as aging or menopause-related and underreported due to embarrassment. Symptoms often normalized as inevitable after childbirth or breastfeeding; consultations focus on the baby, lactation, contraception and obstetric recovery. Proactive questioning is essential. Diagnostic challenge Symptoms should not be better explained by another diagnosis. Symptoms must be distinguished from scar pain, trauma, pelvic floor hypertonicity, infection, dermatoses and psychosocial factors. A strong differential diagnosis section is essential. Clinical priority Long-term symptom relief, tissue health, sexual function and prevention of recurrent urinary symptoms. Breastfeeding-supportive relief, vulvovaginal comfort, sexual wellbeing and quality of life without undermining lactation. Management should explicitly support breastfeeding. Management considerations Non-hormonal moisturizers/lubricants, local hormonal therapy, selected alternatives and long-term follow-up. Education, lubricants/moisturizers, vulvar care, pelvic floor physiotherapy and sexual counselling; low-dose vaginal estrogen may be considered for persistent moderate-to-severe mucosal symptoms. Prasterone lacks lactation-specific evidence. Avoid both reflexive hormone avoidance and universal hormone prescribing; use shared decision-making and phenotype-directed care. Evidence base Broader literature, consensus terminology, clinical trials and management guidelines. Emerging literature, recent conceptual proposal, recent systematic review, limited interventional data and no universally accepted criteria. The article’s contribution is a practical clinical framework and research agenda.
Genitourinary syndrome of menopause and genitourinary syndrome of lactation: similarities and differences.
However, the analogy should be used as a bridge, not as a substitution. GSL should not be described simply as GSM in a younger woman. The menopausal transition and the lactation period differ in chronology, physiology, expectations and clinical meaning. GSM usually occurs in the context of ovarian aging and is often persistent without treatment. GSL occurs after pregnancy and birth, in a period in which ovarian activity is suppressed in association with breastfeeding and in which symptoms may change as lactation intensity changes or after weaning. This potentially reversible natural history should be reflected in the way clinicians counsel women.
The emotional and relational context is also different. A woman with GSM may be navigating midlife, aging, chronicity and long-term sexual adaptation. A woman with GSL may be recovering from a vaginal birth, cesarean delivery, perineal trauma or pelvic floor dysfunction while breastfeeding day and night, sleeping poorly, negotiating body image changes and trying to resume intimacy while caring for an infant. In that setting, vulvovaginal dryness or superficial dyspareunia is not merely a tissue symptom. It may alter sexual confidence, generate avoidance, create misunderstanding within the couple and reinforce the idea that postpartum discomfort must simply be endured.
This is why GSL requires a specific clinical identity. Keeping the postpartum context explicit helps prevent direct transfer of menopausal assumptions to a physiologically distinct state. Conversely, the GSM framework remains useful because it integrates genital, sexual and urinary effects of reduced sex-steroid activity. The strength of the GSL concept lies in using that integrated genitourinary logic while adapting it to the physiology, natural history and care needs of breastfeeding women.
For these reasons, GSL should be understood as a related but distinct syndrome. It shares with GSM the insight that reduced sex steroid activity can affect the lower genital and urinary tract, but it belongs to the postpartum period. Its recognition should prompt clinicians to ask better questions, examine carefully when indicated, consider differential diagnoses and offer women a pathway of care that respects both breastfeeding and maternal quality of life.
The biological plausibility of GSL rests on the interaction between lactation-associated endocrine suppression, postpartum genital tract recovery and the hormone-sensitive nature of the lower genitourinary tract. After delivery, placental estrogen and progesterone concentrations fall abruptly. Repeated suckling maintains prolactin secretion. Contemporary neuroendocrine models describe suppression of hypothalamic kisspeptin signalling and gonadotropin-releasing hormone pulsatility, with reduced luteinizing hormone pulse frequency and delayed follicular maturation, ovulation and ovarian estradiol production. 8 , 9 The intensity and duration of this suppression vary with feeding frequency, night feeds, supplementation and time since birth. Exclusive and frequent breastfeeding can therefore maintain functional hypoestrogenism well beyond the immediate puerperium, particularly while amenorrhea persists. Direct observations during prolonged lactation found that estradiol rose over time but remained particularly low in women who remained amenorrheic while prolactin remained elevated.
10
The contribution of reduced androgen activity is less clearly characterized and remains a hypothesis rather than an established mechanism.
Clinical data support the relevance of this hypoestrogenic state. In a postpartum study evaluating symptoms in breastfeeding and bottle-feeding women, Agarwal et al. found that breastfeeding women were more likely to report vaginal dryness at both 3 and 6 weeks postpartum, whereas hot flashes did not differ similarly between groups.
11
These findings are important because they suggest that lactation-related hypoestrogenemia may preferentially affect tissues with a lower estrogen threshold, such as the vaginal mucosa, without necessarily producing the full systemic symptom profile typically associated with menopause. For GSL, this distinction is clinically useful: the absence of vasomotor symptoms should not lead clinicians to dismiss a local hypoestrogenic mechanism.
The vagina, vestibule, vulva, urethra and bladder are hormonally responsive tissues. In GSM, estrogen deficiency is associated with thinning of the vaginal epithelium, reduced lubrication, decreased elasticity, changes in vascularity and connective tissue, increased pH, altered microbiota, mucosal fragility and urinary symptoms. 5 , 12 These mechanisms cannot be transferred uncritically to lactation, because menopause and breastfeeding differ in duration, systemic context and natural history. Nevertheless, they provide a biologically coherent model for understanding why lactating women may experience dryness, burning, introital discomfort, dyspareunia and urinary complaints in the absence of infection or another dominant diagnosis.
A key element is the vaginal epithelium. Estrogen promotes epithelial maturation and glycogen accumulation, which in turn supports lactobacilli and acidic vaginal conditions. 13 , 14 When estrogen levels fall, epithelial maturation and lubrication may decrease, tissue may become more fragile and the vaginal environment may become less lactobacillus-dominant and more diverse. In the postpartum period, this hormonal trajectory overlaps with the abrupt biological transition of delivery. Costello et al. showed that childbirth is associated with a pro-inflammatory vaginal cytokine response and loss of Lactobacillus dominance, with delayed recovery of the vaginal ecosystem for some women during the postpartum year.
13
This does not prove that all postpartum microbial changes are caused by lactation, but it reinforces that the postpartum vaginal environment is biologically dynamic and potentially vulnerable.
Another important point is that GSL is unlikely to have a single pathophysiological pathway. In clinical practice, lactation-associated hypoestrogenism may act as a primary mechanism in some women, as an aggravating factor in others, and as one component of a broader postpartum pain or sexual dysfunction phenotype. A woman with mild mucosal dryness may become symptomatic only when attempting penetration after perineal trauma or in the presence of pelvic floor hypertonicity. Another may experience urinary urgency in the context of both hypoestrogenic tissue changes and pelvic floor dysfunction. This layered model is essential because it prevents both underrecognition and overdiagnosis.
For this reason, GSL is best understood through an integrated postpartum model. Lactation-induced hormonal deprivation occurs in tissues already influenced by childbirth, local inflammation, microbial transition, perineal healing and pelvic floor adaptation. Sleep deprivation, altered sexual arousal and psychosocial change may also affect symptom severity. This model supports proactive screening, careful examination when indicated and individualized management rather than a single therapeutic response.
GSL should not be reduced to vaginal dryness, even though dryness is probably its most recognizable symptom. The emerging literature describes a broader constellation of vulvovaginal, urinary and sexual symptoms in postpartum breastfeeding women, with substantial overlap between local tissue discomfort, sexual pain and quality-of-life impairment.4,6,13 Clinically, the value of the syndrome lies in this integrated view: symptoms that might otherwise be considered unrelated can be considered together, provided that alternative or coexisting diagnoses are actively assessed.
Vulvovaginal symptoms are often the most direct expression of the condition. Women may report vaginal dryness, burning, irritation, introital discomfort, pruritus, fissuring, reduced lubrication or a sense that the vagina feels more fragile or less comfortable than before pregnancy. 4 , 6 These symptoms may be spontaneous, but they are frequently more evident during sexual activity, tampon use, gynaecological examination or daily activities involving friction. Importantly, some women may not use medical language to describe the symptom. They may speak of feeling raw, uncomfortable, different or not ready, expressions that require sensitive clinical exploration rather than immediate reassurance alone.
The sexual dimension of GSL is central. Postpartum sexuality is influenced by hormonal changes, physical recovery, fatigue, mental health, breastfeeding demands, body image, partner support and cultural expectations. 2 , 3 , 15 In breastfeeding women specifically, a recent systematic review found that breastfeeding is associated with changes in sexual function, including decreased libido, vaginal dryness, dyspareunia and reduced sexual satisfaction, while emphasizing the complex interaction between hormonal, psychological, social and relational factors.
15
For this reason, superficial dyspareunia in a lactating woman should not be interpreted only as a genital symptom. It may also lead to avoidance of intimacy, fear of penetration, reduced sexual confidence, secondary decrease in desire and distress within the couple.
Dyspareunia deserves particular attention because it is one of the symptoms most likely to be normalized after childbirth. In the MAMMI cohort, breastfeeding and pre-existing dyspareunia were associated with sexual health issues at 6 months postpartum, including dyspareunia, lack of vaginal lubrication and loss of interest in sexual activity.
3
Broader postpartum literature also recognizes sexual pain as a frequent and often undertreated symptom after birth. 16 , 17 In the context of GSL, dyspareunia is usually described as superficial or introital, often related to reduced lubrication and mucosal discomfort. However, deep dyspareunia, pain localized to a scar, pelvic floor hypertonicity or vestibular allodynia should prompt reconsideration of the differential diagnosis rather than automatic attribution to lactation-related hypoestrogenism.
Urinary symptoms are part of the proposed genitourinary spectrum, but they require especially careful interpretation. Women may describe urgency, frequency, urethral burning, dysuria-like discomfort with repeatedly negative cultures, recurrent urinary complaints, urinary leakage or postcoital urinary discomfort. 4 , 6 Some symptoms may plausibly reflect reduced estrogenic support of urethral and periurethral tissues, but postpartum urinary complaints are also commonly related to pelvic floor dysfunction, birth trauma, infection, bladder pain syndrome, voiding dysfunction or incontinence mechanisms unrelated to lactation. A systematic review and meta-analysis reported a pooled postpartum urinary incontinence incidence of 26%.
18
Urinalysis or culture is appropriate when infection is suspected, and persistent culture-negative symptoms require reassessment rather than repeated empirical antibiotics. Urinary symptoms may be relevant to GSL, but they are not diagnostically specific.
Bowel symptoms are not part of the proposed genitourinary definition of GSL, but they are clinically relevant. Constipation, obstructed defecation, fecal or flatal urgency or incontinence, and pain related to obstetric anal sphincter injury may coexist with dyspareunia and urinary complaints as part of broader postpartum pelvic floor morbidity.
17
Their presence should prompt enquiry about severe perineal trauma, mode of birth and pelvic floor function, with specialist referral when indicated.
Quality-of-life impairment is not a secondary issue. For some women, symptoms may be mild and self-limited; for others, they may affect self-image, relationship dynamics, sexual identity, emotional wellbeing and the experience of breastfeeding itself. 15 , 16 A woman may strongly wish to continue breastfeeding while also feeling distressed by genital discomfort, urinary symptoms or sexual avoidance. This apparent contradiction should not be interpreted as ambivalence toward breastfeeding, but as evidence that maternal health and infant feeding are not competing priorities. A breastfeeding-supportive model should be able to hold both realities at the same time.
A practical way to understand the clinical phenotype is to consider overlapping domains: mucosal or hormonal symptoms, scar or vestibular pain, pelvic floor and urinary dysfunction, bowel or broader obstetric pelvic floor injury, sexual dysfunction and psychosocial impact. Not every woman will present all domains, and not every symptom will be caused by lactation-induced hypoestrogenism. Mixed presentations are common. This heterogeneity strengthens, rather than weakens, the need for a structured clinical approach.
The clinical usefulness of GSL depends on preserving clear diagnostic boundaries. Because no universally accepted diagnostic criteria currently exist, symptoms compatible with GSL should be considered a reason for focused assessment rather than a reason for immediate diagnostic closure. Postpartum vulvovaginal, urinary and sexual symptoms are frequently multifactorial, and lactation-associated hypoestrogenism may coexist with childbirth-related trauma, pelvic floor dysfunction, infection, vulvar pain disorders, urinary disease or psychosocial distress. The main differential diagnoses and contributing factors are summarized in Table 2 . Table 2. Differential diagnosis of postpartum vulvovaginal, urinary, bowel and sexual symptoms. Condition or contributing factor How it may resemble GSL Clinical clues Initial assessment Management implication GSL-compatible presentation Dryness, burning, reduced lubrication, superficial dyspareunia and urinary discomfort during breastfeeding. Symptoms begin or worsen during exclusive or prolonged breastfeeding; mucosal dryness or fragility without another dominant cause. Focused postpartum, lactation, sexual and urinary history; examination when appropriate; exclude infection, trauma, dermatoses and pelvic floor disorders. Breastfeeding-supportive care: education, validation, lubricants, moisturizers, vulvar care and individualized therapies. Perineal scar tenderness, episiotomy or obstetric tears Superficial dyspareunia, introital pain and avoidance of intercourse may be attributed to dryness. Localized scar or posterior fourchette pain; tenderness on palpation; history of episiotomy, operative delivery or tear. Visual inspection, gentle palpation, assessment of wound healing and granulation tissue. Scar-specific care, topical measures, pelvic floor physiotherapy, treatment of granulation tissue or revision in selected cases. Pelvic floor hypertonicity or myofascial pain Dyspareunia, burning, urinary urgency and postcoital pain may overlap with GSL. Pain with palpation of levator ani, obturator internus or pelvic sidewall; increased resting tone; difficulty relaxing. Single-digit pelvic floor examination, assessment of tone, trigger points and ability to contract and relax. Pelvic floor physiotherapy focused on down-training, manual therapy, relaxation and graded return to sexual activity. Provoked vestibulodynia or vulvodynia Burning, introital pain and penetration-related discomfort can mimic hypoestrogenic mucosal pain. Pain localized to the vestibule, provoked by touch, tampon use or penetration; cotton-swab tenderness; persistence beyond lactation. Cotton-swab test, pain mapping, evaluation for pelvic floor hypertonicity, infection or dermatosis. Multidisciplinary vulvar pain management, pelvic floor therapy and sexual pain counselling. Vulvovaginal infections Irritation, burning, dysuria-like symptoms, dyspareunia and discharge may overlap with GSL. Abnormal discharge, odor, pruritus, erythema, fissuring or recurrent symptoms. Vaginal pH, microscopy when available, culture or nucleic acid testing; STI testing when indicated. Treat confirmed infection; avoid repeated empirical antifungals without confirmation in recurrent or atypical cases. Urinary tract infection or bladder pain syndrome Dysuria, frequency, urgency and urinary discomfort may be interpreted as part of GSL. Bacteriuria, hematuria, suprapubic pain, fever or recurrent episodes; bladder pain may relate to filling and voiding. Urinalysis, urine culture when indicated, assessment of recurrent UTI risk and bladder pain features. Treat infection when confirmed; evaluate persistent negative-culture symptoms for bladder pain, pelvic floor or urethral pain. Vulvar dermatoses and contact dermatitis Burning, pruritus, fissuring, soreness and sexual pain may be mistaken for atrophy or dryness. White plaques, erosions, architectural changes, excoriations, dermatitis pattern or irritant exposure. Careful vulvar inspection; consider biopsy for suspicious or persistent lesions; review hygiene and product exposure. Specific dermatologic treatment, irritant avoidance and follow-up. Hormonal contraception-related symptoms Reduced lubrication, libido changes and dyspareunia may coexist with lactation-related hypoestrogenism. Temporal relationship with initiation of contraception; systemic mood or libido changes. Review postpartum contraception, timing, bleeding pattern, mood and sexual symptoms. Consider contraceptive counselling and individualized method change when appropriate. Deep dyspareunia from pelvic pathology Sexual pain may be reported simply as postpartum dyspareunia. Deep pelvic pain, dysmenorrhea after menses return, chronic pelvic pain, bowel or bladder pain or prior endometriosis. Pelvic examination, transvaginal ultrasound when indicated and targeted evaluation. Investigate and treat underlying pelvic disease; do not manage as GSL alone. Pelvic organ prolapse and broader pelvic floor dysfunction Urinary symptoms, sexual discomfort and vaginal pressure may overlap with GSL. Vaginal bulge, pressure, heaviness, stress urinary incontinence, fecal symptoms or impaired support. Pelvic floor and prolapse assessment, cough stress test when appropriate. Pelvic floor rehabilitation, pessary or urogynecology referral depending on severity and goals. Postpartum depression, anxiety, traumatic birth or relational distress Low desire, avoidance and sexual dissatisfaction may be interpreted as secondary to genital pain alone. Mood symptoms, intrusive memories, fear, exhaustion, relationship conflict or distress unrelated to penetration alone. Sensitive psychosocial history, screening for depression and anxiety, enquiry about birth trauma and relationship context. Integrate psychological, sexual and relational support; genital treatment alone may be insufficient. Inadequate arousal, fatigue and practical breastfeeding barriers Reduced lubrication and avoidance may resemble GSL even without marked mucosal findings. Desire-arousal mismatch, exhaustion, interrupted sleep, privacy issues, body image concerns or breast discomfort. Sexual history exploring desire, arousal, fatigue, body image, partner dynamics and expectations. Education, communication strategies, lubricants, gradual resumption of intimacy and couple-centred counselling. Bowel dysfunction or obstetric anal sphincter injury Pelvic pain, avoidance and broader pelvic floor complaints may be reported alongside GSL symptoms. Constipation, obstructed defecation, fecal or flatal urgency or incontinence, severe tear or operative birth. Bowel history, perineal and pelvic floor assessment; specialist investigation when indicated. Bowel management, specialist pelvic floor rehabilitation and colorectal or urogynecology referral when appropriate.
Differential diagnosis of postpartum vulvovaginal, urinary, bowel and sexual symptoms.
Postpartum dyspareunia illustrates the importance of this approach. In a clinical study of women presenting with painful intercourse that began after delivery, Ram-Weiner et al. classified patients according to dominant findings, including muscle hypertonicity, scar tenderness, vestibular tenderness and atrophy.
19
This phenotypic approach is highly relevant to GSL. Atrophy or mucosal dryness may be present, but it may not be the only driver of pain. A woman may have lactation-related dryness and, at the same time, a tender episiotomy scar, pelvic floor overactivity or vestibular sensitivity. In such cases, treating dryness alone is unlikely to resolve the clinical problem.
Perineal scar pain is one of the most important mimics of GSL-related superficial dyspareunia. Localized pain at the posterior fourchette, tenderness on palpation, granulation tissue, a history of episiotomy or operative vaginal delivery, or pain clearly mapped to the site of a tear should redirect clinical attention toward scar-related pathology. Similarly, pelvic floor muscle hypertonicity or myofascial pain can produce introital pain, burning, urinary urgency and postcoital discomfort. These symptoms may be interpreted by the patient as vaginal dryness, but examination may reveal increased resting tone, trigger points or inability to relax the pelvic floor. In these cases, pelvic floor physiotherapy may be more relevant than a purely mucosal treatment strategy.
Provoked vestibulodynia and vulvodynia also require specific attention. The 2015 ISSVD, ISSWSH and IPPS consensus terminology defines vulvodynia as vulvar pain of at least 3 months’ duration without a clear identifiable cause, while recognizing the complexity of vulvar pain presentations and associated factors.
20
In the postpartum and breastfeeding context, vestibular tenderness may be mistaken for hypoestrogenic introital discomfort. Cotton-swab testing, pain mapping, pelvic floor assessment and careful exclusion of infection or dermatosis may be necessary when pain is disproportionate, localized to the vestibule, persistent or not clearly linked to lactation intensity.
Urinary symptoms require similar caution. Urgency, frequency, dysuria-like discomfort and urinary leakage are not specific. Urinary tract infection, recurrent bacteriuria, bladder pain syndrome, urethral pain, voiding dysfunction, pelvic floor dysfunction and postpartum incontinence mechanisms should be considered. 17 , 18 Bowel dysfunction, prolapse and obstetric anal sphincter injury may identify a broader pelvic floor phenotype rather than GSL itself. These symptoms should be integrated into assessment without being automatically attributed to lactation-induced hypoestrogenism.
A practical diagnostic formulation may therefore be preferable to a binary diagnosis. Clinicians can describe a presentation as GSL-compatible when breastfeeding-associated vulvovaginal, urinary or sexual symptoms are present and no better dominant explanation is identified. They can describe it as mixed when GSL-like features coexist with scar pain, pelvic floor dysfunction, vestibular tenderness, infection, dermatosis or psychosocial contributors. This language preserves clinical rigor while allowing the emerging syndrome to be recognized. The aim is not to decide whether a woman has GSL or something else in absolute terms, but to identify which mechanisms are driving her symptoms and to treat them accordingly.
Recognition of GSL requires clinicians to move beyond passive reassurance. Many postpartum women do not spontaneously report vulvovaginal dryness, dyspareunia, urinary discomfort or sexual distress unless a safe and explicit space is created for discussion.3,7 This is particularly relevant during breastfeeding, when women may assume that genital discomfort is inevitable, temporary or too secondary to mention compared with infant feeding, contraception or obstetric recovery. A structured but sensitive screening approach can normalize the conversation without normalizing the suffering.
Screening for GSL should not be limited to the traditional six-week postpartum visit. Symptoms may appear early, but they may also become evident later, particularly when sexual activity is resumed or when exclusive or frequent breastfeeding is maintained for several months. 1 , 17 For this reason, enquiry about genitourinary and sexual symptoms should be incorporated into postpartum care, lactation follow-up, contraceptive counselling, pelvic floor assessment and gynaecological visits during prolonged breastfeeding. The proposed clinical pathway is shown in Figure 1 . Figure 1. Proposed clinical pathway for screening, phenotyping and management of genitourinary syndrome of lactation. Figure legend. Proposed clinical pathway for recognition, differential diagnosis and management of genitourinary syndrome of lactation in postpartum and breastfeeding women. The pathway emphasizes proactive screening, red-flag assessment, identification of mucosal/hormonal and mixed phenotypes, targeted treatment of alternative or coexisting causes, shared decision-making regarding low-dose vaginal estrogen and reassessment of symptoms and breastfeeding experience.
Proposed clinical pathway for screening, phenotyping and management of genitourinary syndrome of lactation.
Figure legend. Proposed clinical pathway for recognition, differential diagnosis and management of genitourinary syndrome of lactation in postpartum and breastfeeding women. The pathway emphasizes proactive screening, red-flag assessment, identification of mucosal/hormonal and mixed phenotypes, targeted treatment of alternative or coexisting causes, shared decision-making regarding low-dose vaginal estrogen and reassessment of symptoms and breastfeeding experience.
A practical screening strategy should explore vulvovaginal discomfort, sexual pain or dysfunction, urinary symptoms, quality-of-life impact and, when relevant, bowel or broader pelvic floor symptoms. The wording should be direct enough to identify symptoms but careful enough to avoid making women feel judged, pressured to resume sexual activity or questioned about their breastfeeding choices. The following questions may be used as a brief clinical tool ( Box 1 ). Clinical Box 1. Suggested screening questions for genitourinary syndrome of lactation
1. Since delivery or during breastfeeding, have you noticed vaginal dryness, burning, irritation or discomfort? 2. If you have resumed sexual activity, have you experienced pain, reduced lubrication or avoidance because of discomfort? 3. Have you developed new urinary symptoms such as urgency, frequency, urethral burning, leakage or recurrent urinary discomfort? 4. Have you noticed constipation, difficulty emptying the bowel, fecal or flatal urgency or incontinence, particularly after a severe tear? 5. Are these symptoms affecting your wellbeing, self-image, relationship or breastfeeding experience? 6. Would you like to discuss options to improve these symptoms while supporting your breastfeeding goals?
1. Since delivery or during breastfeeding, have you noticed vaginal dryness, burning, irritation or discomfort? 2. If you have resumed sexual activity, have you experienced pain, reduced lubrication or avoidance because of discomfort? 3. Have you developed new urinary symptoms such as urgency, frequency, urethral burning, leakage or recurrent urinary discomfort? 4. Have you noticed constipation, difficulty emptying the bowel, fecal or flatal urgency or incontinence, particularly after a severe tear? 5. Are these symptoms affecting your wellbeing, self-image, relationship or breastfeeding experience? 6. Would you like to discuss options to improve these symptoms while supporting your breastfeeding goals?
1. Since delivery or during breastfeeding, have you noticed vaginal dryness, burning, irritation or discomfort?
2. If you have resumed sexual activity, have you experienced pain, reduced lubrication or avoidance because of discomfort?
3. Have you developed new urinary symptoms such as urgency, frequency, urethral burning, leakage or recurrent urinary discomfort?
4. Have you noticed constipation, difficulty emptying the bowel, fecal or flatal urgency or incontinence, particularly after a severe tear?
5. Are these symptoms affecting your wellbeing, self-image, relationship or breastfeeding experience?
6. Would you like to discuss options to improve these symptoms while supporting your breastfeeding goals?
There are currently no specific, universally accepted treatment guidelines for GSL. Management is therefore better framed as a stepped, symptom-guided and breastfeeding-supportive approach than as a fixed protocol. The first task is to validate the woman’s symptoms, identify the dominant mechanisms contributing to them and avoid presenting breastfeeding cessation as the default solution. Recognition of GSL should expand postpartum care, not undermine lactation.
The first therapeutic step is education. Women should be told that vulvovaginal dryness, reduced lubrication, superficial dyspareunia and some urinary discomfort can occur during breastfeeding, particularly when lactation is exclusive or prolonged, and that these symptoms are not a sign of personal failure, poor desire or inadequate adaptation to motherhood. This explanation can reduce guilt, improve communication with the partner and open the door to practical treatment. Education should also include reassurance that sexual activity does not need to resume according to an external timeline. A woman’s comfort, recovery and readiness should guide the process.
For mild to moderate mucosal symptoms, non-hormonal measures are the most appropriate first-line option. This approach is consistent with GSM guidance, in which lubricants during sexual activity and long-acting vaginal moisturizers are considered appropriate first-line therapies for less severe symptoms.
21
Although GSM evidence cannot be directly transferred to lactation, the principle is clinically reasonable: start with measures that improve comfort, reduce friction and support tissue hydration without systemic hormonal exposure. In practice, this includes vulvar care, avoidance of irritants, use of lubricants for sexual activity and regular vaginal moisturizers when dryness is persistent.
Hyaluronic acid-based products merit specific consideration among non-hormonal options. Hyaluronic acid has hygroscopic and tissue-supportive properties and has been studied mainly in postmenopausal vulvovaginal atrophy and other hypoestrogenic contexts. Of particular relevance, a prospective randomized clinical trial evaluated a prolonged-release hyaluronic acid derivative vaginal gel in puerperal women and reported improvements in sexual function, vaginal pH and trophic status of the vaginal epithelium compared with expectant management.20 Because this study was conducted in the postpartum period, it is directly relevant to the discussion of GSL; nevertheless, it should be interpreted cautiously. It supports hyaluronic acid as a plausible non-hormonal strategy, not as definitive evidence for all women with GSL. Product availability, formulation, patient preference, cost and tolerability will vary across settings.
Pelvic floor assessment and rehabilitation should be integrated whenever pain, hypertonicity, urinary symptoms, incontinence, scar tenderness or pelvic floor dysfunction are present. Management should not be reduced to asking women to perform pelvic floor contractions. In women with hypertonic pelvic floor dysfunction or dyspareunia, relaxation, down-training, manual therapy, scar mobilization, breathing work, graded exposure and sexual pain counselling may be more appropriate than strengthening alone. A systematic review and meta-analysis found that pelvic floor muscle training can improve postpartum sexual function and quality of life, although heterogeneity and the need for higher-quality trials were noted.
22
In women with dyspareunia, pelvic floor rehabilitation has also shown benefit in pain and sexual function outcomes.
23
For GSL, this means that pelvic floor physiotherapy should be considered a central part of care when a mixed mucosal-pelvic floor phenotype is suspected.
Low-dose vaginal estrogen should not be framed as a near-contraindicated or exceptional treatment. In GSM it is effective for moderate-to-severe symptoms when non-hormonal measures are insufficient.
21
Pharmacokinetic studies in postmenopausal women generally show low, dose-dependent systemic estradiol exposure with contemporary low-dose vaginal preparations, although these data cannot substitute for lactation-specific studies.
24
Direct lactation-specific evidence is limited, but a pilot randomized trial in primiparous women with perineal laceration found local estradiol acceptable and apparently safe, although clinical benefit was modest.
25
For a woman with persistent moderate-to-severe mucosal symptoms after alternative or coexisting causes have been addressed, low-dose vaginal estrogen is therefore a reasonable option through shared decision-making, particularly once lactation is established. It should not be prescribed automatically to every woman with postpartum dyspareunia because mixed scar, vestibular and pelvic floor phenotypes are common.
Counselling should distinguish contemporary low-dose local therapy from systemic estrogen exposure. As suckling declines, ovarian activity and endogenous estradiol production recover, eventually allowing ovulation and menses to resume.
8
This physiological context makes clear that the relevant question is not avoidance of all estrogen exposure, but the benefit-risk profile of a specific low-dose vaginal formulation. LactMed notes that transfer into milk depends on route and formulation and that estrogens may reduce milk production, especially when introduced before lactation is well established.
26
The revised concern is therefore not presumed infant harm from trace estradiol exposure, for which evidence is lacking, but uncertainty about direct lactation pharmacokinetics and a possible effect on milk supply when treatment is started early. Clinicians should use the lowest effective regimen, consider timing since birth and lactation stability, and reassess symptoms and breastfeeding experience. Routine infant-growth monitoring solely because low-dose vaginal estrogen is used is not supported by current evidence.
Vaginal prasterone should also be acknowledged. Through local intracrine conversion to estrogenic and androgenic metabolites, it has demonstrated efficacy for dyspareunia associated with postmenopausal GSM.
27
However, the prescribing information reports no data on its presence in human milk, effects on the breastfed infant or effects on milk production, and no lactation-specific efficacy studies were identified.
28
It cannot currently be recommended routinely for GSL and is better regarded as a priority for research or specialist consideration until direct evidence becomes available.
Energy-based therapies, including fractional CO2 laser, should not be incorporated into routine GSL management at present. A prospective observational study in postpartum breastfeeding women with vulvovaginal atrophy reported subjective and objective improvements after fractional CO2 laser treatment.
29
However, the evidence remains preliminary, non-randomized and insufficient to support routine use in this population. Given cost, access, safety considerations and the broader uncertainty surrounding energy-based vaginal treatments, these interventions should be reserved for research settings or highly selected specialist contexts until better comparative and long-term safety data are available.
A practical management pathway can therefore be summarized as follows: validate and phenotype the symptoms, begin breastfeeding-supportive non-hormonal measures, treat coexisting scar, pelvic floor, urinary, bowel, infectious, dermatological or psychosocial contributors, and consider low-dose vaginal estrogen through shared decision-making for persistent moderate-to-severe mucosal symptoms. Vaginal prasterone should not be used routinely in the absence of lactation-specific evidence. Reassessment is essential when response is incomplete.
Research on GSL remains at an early stage. Current literature supports biological plausibility and clinical relevance, but important uncertainties remain regarding definition, prevalence, natural history, diagnostic criteria and management.4,6 A research agenda is needed not only to validate the syndrome, but also to prevent imprecise use of the term. Without better evidence, GSL could remain invisible in postpartum care or become an overly broad label for heterogeneous symptoms. Both outcomes would be clinically undesirable.
The first priority is a consensus definition. At present, GSL is best understood as a breastfeeding-associated pattern of vulvovaginal, urinary and sexual symptoms plausibly related to lactation-induced hormonal deprivation after exclusion of a better dominant explanation. 4 , 6 However, this working definition requires refinement. Future consensus work should determine which symptoms are core, which signs are supportive, how lactation status should be incorporated, whether symptom duration should be specified and how mixed presentations should be classified. A practical definition should be narrow enough to preserve diagnostic value but broad enough to reflect the real-world overlap between mucosal, urinary, sexual and pelvic floor symptoms.
Prevalence estimates are another major gap. The recent systematic review by Perelmuter et al. highlights that vaginal dryness, atrophy, dyspareunia, urinary symptoms and sexual dysfunction are common among postpartum and lactating women, but available studies differ in populations, timing, definitions and outcome measures.
6
Future epidemiological studies should stratify women by exclusive breastfeeding, mixed feeding, formula feeding, duration and intensity of lactation, time since birth, mode of delivery, parity, perineal trauma, contraception and resumption of menses. These variables are essential because a woman breastfeeding exclusively at 4 months postpartum is not biologically or clinically equivalent to a woman partially breastfeeding at 12 months or a woman who has recently weaned.
Therapeutic trials are urgently needed, but they must be designed carefully. Non-hormonal treatments such as lubricants, vaginal moisturizers and hyaluronic acid-based products are attractive first-line candidates because they are compatible with breastfeeding goals and avoid systemic hormonal exposure. 21 , 30 However, postpartum and lactation-specific randomized trials are still limited. Future studies should compare different non-hormonal strategies, evaluate frequency and duration of use, measure sexual comfort and quality of life, and include tolerability, adherence and acceptability outcomes. They should also avoid restricting endpoints to vaginal pH or maturation indices alone, because the clinically meaningful outcome is whether the woman feels better, safer and more able to resume intimacy if she wishes.
The role of local vaginal estrogen requires rigorous investigation. Existing postpartum data suggest acceptability and apparent safety in a small trial but only modest clinical benefit.
25
Lactation-specific studies should evaluate timing, dose, formulation, symptom response, milk supply, infant outcomes and patient preferences.
26
Vaginal prasterone also requires dedicated pharmacokinetic and clinical study before it can be considered for routine use during breastfeeding ( Box 2 ). Box 2. Priority research areas for genitourinary syndrome of lactation
1. Consensus diagnostic definition and terminology. 2. Prevalence by lactation type, duration and intensity. 3. Natural history before and after return of menses or weaning. 4. Validated symptom and quality-of-life instruments for postpartum breastfeeding women. 5. Hormonal, epithelial, pH, microbiome and inflammatory correlates. 6. Differentiation of mucosal, scar, pelvic floor, vestibular, urinary, bowel and mixed phenotypes. 7. Randomized trials of non-hormonal treatments, including hyaluronic acid-based vaginal moisturizers. 8. Carefully designed studies of low-dose vaginal estrogen during established lactation. 9. Lactation pharmacokinetic and clinical studies of vaginal prasterone. 10. Combined care pathways integrating pelvic floor physiotherapy and sexual counselling. 11. Implementation studies assessing screening, clinician education and postpartum care pathways.
1. Consensus diagnostic definition and terminology. 2. Prevalence by lactation type, duration and intensity. 3. Natural history before and after return of menses or weaning. 4. Validated symptom and quality-of-life instruments for postpartum breastfeeding women. 5. Hormonal, epithelial, pH, microbiome and inflammatory correlates. 6. Differentiation of mucosal, scar, pelvic floor, vestibular, urinary, bowel and mixed phenotypes. 7. Randomized trials of non-hormonal treatments, including hyaluronic acid-based vaginal moisturizers. 8. Carefully designed studies of low-dose vaginal estrogen during established lactation. 9. Lactation pharmacokinetic and clinical studies of vaginal prasterone. 10. Combined care pathways integrating pelvic floor physiotherapy and sexual counselling. 11. Implementation studies assessing screening, clinician education and postpartum care pathways.
1. Consensus diagnostic definition and terminology.
2. Prevalence by lactation type, duration and intensity.
3. Natural history before and after return of menses or weaning.
4. Validated symptom and quality-of-life instruments for postpartum breastfeeding women.
5. Hormonal, epithelial, pH, microbiome and inflammatory correlates.
6. Differentiation of mucosal, scar, pelvic floor, vestibular, urinary, bowel and mixed phenotypes.
7. Randomized trials of non-hormonal treatments, including hyaluronic acid-based vaginal moisturizers.
8. Carefully designed studies of low-dose vaginal estrogen during established lactation.
9. Lactation pharmacokinetic and clinical studies of vaginal prasterone.
10. Combined care pathways integrating pelvic floor physiotherapy and sexual counselling.
11. Implementation studies assessing screening, clinician education and postpartum care pathways.
Several limitations should be acknowledged. First, GSL is an emerging concept and lacks universally accepted diagnostic criteria. Some elements of the proposed framework are therefore based on synthesis and interpretation of related evidence rather than on direct GSL-specific trials. Second, several mechanisms discussed here are biologically plausible but partly extrapolated from GSM, lactational physiology and postpartum sexual health literature. Such extrapolations are clinically useful, but they should not be mistaken for definitive causal proof. Third, postpartum vulvovaginal, urinary and sexual symptoms are heterogeneous and often multifactorial, making it difficult to isolate the specific contribution of lactation-induced hormonal deprivation. Finally, therapeutic evidence remains limited, particularly for lactation-specific efficacy and safety of local hormonal therapy and emerging interventions. The proposed pathway should therefore be read as a pragmatic clinical framework to guide assessment and care, not as a formal guideline.